| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Rodney J. Hicks | Q43224607 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lung cancer | Q47912 |
| Fluorodeoxyglucose Positron Emission Tomography | Q130273243 | ||
| P304 | page(s) | 31S-42S | |
| P577 | publication date | 2009-04-20 | |
| P1433 | published in | The Journal of Nuclear Medicine | Q7743608 |
| P1476 | title | Role of 18F-FDG PET in assessment of response in non-small cell lung cancer | |
| P478 | volume | 50 Suppl 1 |
| Q37253248 | (18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib |
| Q38838770 | A Comparison of microCT and microPET for Evaluating Lymph Node Metastasis in a Rat Model |
| Q84606489 | A method of adjusting SUV for injection-acquisition time differences in (18)F-FDG PET imaging |
| Q47563435 | Characteristics of Smoothing Filters to Achieve the Guideline Recommended Positron Emission Tomography Image without Harmonization |
| Q47966288 | Clinical applications of textural analysis in non-small cell lung cancer. |
| Q42908899 | Comparison of 18F-Fluoroerythronitroimidazole and 18F-Fluorodeoxyglucose Positron Emission Tomography and Prognostic Value in Locally Advanced Non–Small-Cell Lung Cancer |
| Q36569753 | Comparison of CT volumetric measurement with RECIST response in patients with lung cancer |
| Q52982678 | Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer. |
| Q36295403 | Computerized PET/CT image analysis in the evaluation of tumour response to therapy |
| Q48137122 | Correlation of early PET findings with tumor response to molecular targeted agents in patients with advanced driver-mutated non-small cell lung cancer. |
| Q34779180 | Current status of methods to assess cancer drug resistance |
| Q36154024 | Does early PET/CT assesment of response to chemotherapy predicts survival in patients with advanced stage non-small-cell lung cancer? |
| Q47388017 | EANM/EARL FDG-PET/CT accreditation - summary results from the first 200 accredited imaging systems |
| Q37324886 | Early 18F-FDG uptake as a reliable imaging biomarker of T790M-mediated resistance but not MET amplification in non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors |
| Q40475342 | Evaluation of in vivo quantification accuracy of the Ingenuity-TF PET/MR. |
| Q30645097 | Evaluation of strategies towards harmonization of FDG PET/CT studies in multicentre trials: comparison of scanner validation phantoms and data analysis procedures. |
| Q52987662 | FDG PET/CT for assessing the resectability of NSCLC patients with N2 disease after neoadjuvant therapy. |
| Q35208087 | FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy. |
| Q88727989 | FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC |
| Q52676354 | Feasibility of state of the art PET/CT systems performance harmonisation. |
| Q36920672 | Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients. |
| Q43122491 | High FDG uptake in PET/CT predicts worse prognosis in patients with metastatic gastric adenocarcinoma |
| Q36337232 | How to study optimal timing of PET/CT for monitoring of cancer treatment |
| Q44673116 | Imaging the early response to chemotherapy in advanced lung cancer with diffusion-weighted magnetic resonance imaging compared to fluorine-18 fluorodeoxyglucose positron emission tomography and computed tomography. |
| Q44969342 | Impact of rigid and nonrigid registration on the determination of 18F-FDG PET-based tumour volume and standardized uptake value in patients with lung cancer |
| Q30594766 | Introduction to the analysis of PET data in oncology |
| Q34786518 | Metabolic positron emission tomography imaging in cancer detection and therapy response |
| Q38451242 | Metabolic response evaluated by 18F-FDG PET/CT as a potential screening tool in identifying a subgroup of patients with advanced non-small cell lung cancer for immediate maintenance therapy after first-line chemotherapy |
| Q34496670 | Molecular imaging in cancer treatment |
| Q37681293 | Monitoring tumour response during chemo-radiotherapy: a parametric method using FDG-PET/CT images in patients with oesophageal cancer. |
| Q36567875 | Multicenter Clinical Trials Using 18F-FDG PET to Measure Early Response to Oncologic Therapy: Effects of Injection-to-Acquisition Time Variability on Required Sample Size. |
| Q58765546 | Multicentre analysis of PET SUV using vendor-neutral software: the Japanese Harmonization Technology (J-Hart) study |
| Q36143279 | Multiplexed imaging in cancer diagnosis: applications and future advances |
| Q64985818 | New PET/CT Features for the Evaluation of Tumor Response. |
| Q35093270 | New targeted molecular therapies for cancer: radiological response in intrathoracic malignancies and cardiopulmonary toxicity: what the radiologist needs to know |
| Q37927164 | Novel molecular imaging in lung and pleural diseases |
| Q34987711 | PET imaging of apoptosis in tumor-bearing mice and rabbits after paclitaxel treatment with (18)F(-)Labeled recombinant human His10-annexin V. |
| Q34416358 | PET imaging of lung inflammation with [18F]FEDAC, a radioligand for translocator protein (18 kDa). |
| Q38444980 | PET in the management of locally advanced and metastatic NSCLC. |
| Q42961501 | PET/CT for diagnostics and therapy stratification of lung cancer |
| Q37784771 | PET/CT in cancer research: from preclinical to clinical applications. |
| Q38819166 | Present and future roles of FDG-PET/CT imaging in the management of lung cancer. |
| Q36303765 | Promise and pitfalls of quantitative imaging in oncology clinical trials. |
| Q33857343 | RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline |
| Q34218478 | Semi-automatic analysis of standard uptake values in serial PET/CT studies in patients with lung cancer and lymphoma |
| Q88691095 | Serum SP70 is a sensitive predictor of chemotherapy response in patients with advanced nonsmall cell lung cancer |
| Q34681069 | State of the art: Response assessment in lung cancer in the era of genomic medicine |
| Q59126436 | The 18F-FDG PET/CT response to radiotherapy for patients with spinal metastasis correlated with the clinical outcomes |
| Q53107664 | The predictive value of treatment response using FDG PET performed on day 21 of chemoradiotherapy in patients with oesophageal squamous cell carcinoma. A prospective, multicentre study (RTEP3). |
| Q38028536 | The role and future potential of fluorinated biomarkers in positron emission tomography |
| Q38232757 | The role of texture analysis in imaging as an outcome predictor and potential tool in radiotherapy treatment planning |
| Q90713907 | Transcriptomics in cancer revealed by Positron Emission Tomography radiomics |
| Q40200536 | Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NS |
| Q87877317 | Utilization of a hybrid finite-element based registration method to quantify heterogeneous tumor response for adaptive treatment for lung cancer patients |
| Q57990669 | Why harmonization is needed when using FDG PET/CT as a prognosticator: demonstration with EARL-compliant SUV as an independent prognostic factor in lung cancer |
Search more.